On Thursday, STAT published a story claiming that IBM is halting sales of Watson for Drug Discovery — a service that uses the company’s Watson AI to analyze connections between genes, drugs, and diseases on the hunt for useful new medications — citing as its source a person familiar with IBM’s internal decision-making.
“We are focusing our resources within Watson Health to double down on the adjacent field of clinical development where we see an even greater market need for our data and AI capabilities,” an IBM spokesperson told STAT — a sign that eight years after launching Watson Health, IBM still isn’t quite sure how AI should factor into the future of healthcare.
The STAT source cited a “lackluster financial performance” as IBM’s reason for no longer developing and selling Watson for Drug Discovery. That mirrors the “lack of demand” reasoning IBM gave for scaling back the part of Watson Health dedicated to helping hospitals manage certain contracts in June 2018.
To Read Complete Article Click on the above link: https://futurism.com/the-byte/ibm-watson-ai-drug-discovery
Image Courtesy: Futurism.com
USA Network – Your Ultimate TV Schedule & Listings Guide
In today’s fast-paced world, keeping up with your favorite television shows can be a challenge. With multiple networks and streaming…
What to Look for in a Payment Orchestration Platform
Recently, electronic payment has made remarkable advancements, leading to replacing cash in many global markets. However, as businesses expand, they…
Review IBM PULLS THE PLUG ON DRUG-DISCOVERING WATSON AI – By Vikram Rajoori.